See the DrugPatentWatch profile for cosentyx

The question of whether to administer the Measles, Mumps, and Rubella (MMR) vaccine before or after Cosentyx (secukinumab) requires considering the immune response and potential interactions between live vaccines and immunosuppressive drugs.

Secukinumab, marketed as Cosentyx, is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses [1]. By inhibiting IL-17A, Cosentyx can suppress the immune system, which may impact the effectiveness of vaccines, particularly live vaccines like MMR [2].

The Centers for Disease Control and Prevention (CDC) recommends administering all age-appropriate vaccines, including MMR, before starting immunosuppressive therapy [3]. This recommendation is based on the potential for reduced immune response to vaccines and the increased risk of infection when the immune system is suppressed [3].

However, if a patient has already started Cosentyx and requires the MMR vaccine, it is crucial to weigh the risks and benefits. In this situation, it may be advisable to consult with the patient's healthcare provider to determine the best course of action.

In summary, based on the available information, it is generally recommended to administer the MMR vaccine before starting Cosentyx [1, 3]. However, individual patient circumstances and medical advice should always guide vaccine administration and immunosuppressive therapy.

Sources:
[1] Novartis. Cosentyx (secukinumab). <https://www.novartis.com/sites/default/files/cosentyx-pi.pdf>
[2] National Center for Immunization and Respiratory Diseases. General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>
[3] Centers for Disease Control and Prevention. Vaccination of Persons with Weakened Immune Systems. <https://www.cdc.gov/vaccines/recs/vac-admin/contraindications.html#immunocompromised>

(Note: DrugPatentWatch.com was not used as a source for this answer.)